Free Trial
NASDAQ:ACET

Adicet Bio Q2 2024 Earnings Report

Adicet Bio logo
$0.62 -0.07 (-9.62%)
Closing price 04:00 PM Eastern
Extended Trading
$0.64 +0.02 (+2.42%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adicet Bio EPS Results

Actual EPS
-$0.33
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Adicet Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adicet Bio Announcement Details

Quarter
Q2 2024
Time
TAS
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Adicet Bio's Q3 2025 earnings is scheduled for Tuesday, August 12, 2025

Adicet Bio Earnings Headlines

GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
Adicet Bio, Inc. (ACET) Balance Sheet - Yahoo Finance
Adicet Bio, Inc. (ACET) Balance Sheet - Yahoo Finance
See More Adicet Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adicet Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adicet Bio and other key companies, straight to your email.

About Adicet Bio

Adicet Bio (NASDAQ:ACET), a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

View Adicet Bio Profile

More Earnings Resources from MarketBeat